Breakthrough Gene Therapy for Childhood Dementia: Hope and Reality for Families in 2026
A groundbreaking gene therapy has received FDA approval for CLN3 Batten disease, offering a new hope for children and families affected by this rare, fatal neurological condition. While not a cure, the therapy demonstrates the potential to slow disease progression, but faces significant challenges regarding cost and access. Continued research and advocacy are crucial to expanding treatment options and improving the lives of those living with Batten disease.
